In a recently updated edition, the forecast valuation of US$ 758.5 million in 2024 comes from the common thread of influences governing demand for menopause treatments. As these trends gain significance and become mainstream, sales of menopause treatment products hold the potential to stroke the valuation and acquire US$ 1,308.00 million by 2034. This stipulates a steady CAGR of 5.6% from 2024 to 2034.
The proliferating need for personalized treatment options presents a significant opportunity for menopause treatment providers. Every woman's menopausal experience is different and intricate, with distinctive symptoms and barriers. More people are realizing the importance of tailored care in effectively controlling menopausal symptoms.
The menopause treatment market witnesses an upward trajectory due to rising rates of post-menopausal syndrome, thriving awareness of menopause-related health conditions, and growing acceptability of women's health applications. The market is maturing due to a surge in campaigns by major menopause treatment providers to enhance awareness of women's health and the advantages of nutritional supplements.
| Attributes | Details |
|---|---|
| Market Value for 2024 | US$ 758.5 million |
| Market Value for 2034 | US$ 1,308.00 million |
| Market CAGR from 2024 to 2034 | 5.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
To strengthen access of patients to menopause treatments the providers are conferring digital health and telemedicine platforms. The collaboration of telemedicine providers and menopause treatment providers results in the enhancement of patient awareness, support, and treatment process compliance.
Traditional hormone replacement therapy (HRT) got out of trend, with bioidentical hormone therapy (BHT) picking up steam. The menopause treatment providers benefit from this emerging trend by making BHT products and providing customized treatment alternatives tailored to individual requirements.
| Attributes | Details |
|---|---|
| Market Value for 2019 | US$ 499.4 million |
| Market Value for 2023 | US$ 749.5 million |
| Market CAGR from 2019 to 2023 | 7.80% |
The segmented market analysis of menopause treatments shows that the hormone therapy segment is overshadowing other product categories. On the other hand, the oral sector is governing the route of administration category.
| Segment | Hormone Therapy |
|---|---|
| Share (2024) | 62.40% |
The hormone therapy segment acquires a market share of 62.40% in 2024. The productive and widely recognized method of menopausal treatment of heat flashes is estrogenic medication, spurring market growth. Hormone therapy has been broadly recognized for a long period because of its efficiency and the progress it brings to women’s health.
| Segment | Oral |
|---|---|
| Share (2024) | 58.80% |
The oral route of the administration segment garners a market share of 58.8% in 2024. Oral drugs are the easiest, most affordable, and most portable, resulting in the market's surged adoption of oral medications. The contamination rate in oral drug formulations is deemed the lowest, making the oral route of administration lucrative. The oral mode of administration is the accessible, cost-effective, and widely used medication mode.
Principal Consultant
The menopause treatment market is examined in the table below, which concentrate on the dominating regions in North America, Europe, and Asia Pacific. An extensive menopause treatment market analysis demonstrates that Europe has considerable market opportunities.
Opportunities for Menopause Treatment in Europe
| Countries | CAGR (2024 to 2034) |
|---|---|
| Italy | 5.80% |
| Germany | 5.60% |
| France | 5.20% |
| Spain | 4.60% |
| United Kingdom | 4.40% |
The Italy menopause treatment product market is ushered by a preference for natural treatments, traditional herbal remedies and substitute drugs play a significant role. Women in Italy look out for hormone therapy customized to their symptoms and health requirements during menopause, which thrives the menopause treatment market growth.
The public health programs of Italy strongly emphasize education and awareness efforts to de-stigmatize menopause and inspire women to seek healthcare on a regular basis.
Menopause clinics and specialized healthcare centers are emerging in Germany, which indicates a surging demand for extensive care for menopausal women. The inclination toward digital health platforms and telemedicine services among German women provides handy access to necessary information and menopause-related consultations, bolsters the demand for menopause treatments.
The menopausal clinics and other specialist healthcare services are set up due to the advancing awareness of menopause as a disorder that occurs with aging requiring specific treatment. To give patients comprehensive treatment choices, France’s healthcare providers are incorporating complementary therapies like acupuncture, yoga, and osteopathy into menopause management strategies. This trend indicates a surge in menopause treatments sales in France.
Exhibiting a cultural transition for natural solutions to health, women in Spain move to traditional Mediterranean eating habits and integrate herbal medicines like red clover and sage to manage menopause symptoms. Menopause education and support campaigns are prevailing that cater to women the awareness and information required to face this life change, ushering the menopause treatment product market growth in Spain
Workplace policies are evolving into menopause-friendly and are prevalent in the United Kingdom, and these actions help to create a friendly and encouraging environment for women going through menopause. Smartphone applications and digital health platforms are pervasive in the United Kingdom.
These data sources support women with ease of access to self-management tools, menopausal education, and teleconsultations. In light of this trend the menopause wellness market is on the path to witness significant expansion.
Sales Analysis of Menopause Treatment in North America
| Countries | CAGR (2024 to 2034) |
|---|---|
| Canada | 4.10% |
| United States | 3.00% |
The booming expenses of healthcare and broadening healthcare infrastructure in the United States bolster the adoption of menopause treatments, mainly in rural areas. The soaring research and development activities in Canada concentrate on the innovation of non-hormonal therapies, which coincide with the choices of women looking for replacements that cause minimal side effects.
Opportunities in the Asia Pacific Menopause Treatment Industry
| Countries | CAGR (2024 to 2034) |
|---|---|
| China | 3.20% |
| South Korea | 2.40% |
| Japan | 1.60% |
Traditional Chinese medicine is highly instrumental in managing menopausal symptoms and accelerating menopause treatment market growth. As customers seek natural remedies and herbal supplements, this flourishes the adoption of menopause treatments in China.
Society’s perception of menopause is changing, which has led to the escalated adoption of menopause treatments in South Korea. Better access to innovation in technology and healthcare infrastructure amplifies the menopause treatment market growth in South Korea.
Reliable menopausal treatments are in demand in Japan due to the country's aging population and evolving population demographics. Women have an array of choices for controlling menopausal symptoms because of the coexistence of modern therapeutic approaches and traditional Japanese medicine, such as Kampo therapy. These factors intensify the adoption of menopause treatments in Japan.
Several menopause treatment providers dominate the competitive landscape, propelling developments and determining the market shift. Renowned pharmaceutical companies such as Eli Lilly and Company, Merck KGaA, Novartis AG, Bayers AG, and Pfizer, Inc. are at the vanguard. These menopause treatment providers' comprehensive expertise and resources make them essential for market growth.
The prominent menopause treatment vendors comprise Novo Nordisk, Ascend Therapeutics, Mylan N.V. [Viatris], Cipla, Inc., and Glenmark Pharmaceuticals Ltd., each bringing their diverse strengths and product portfolio. Emerging menopause treatment creators like MenoGeniX, Perrigo Pharma International D.A.C., Ausio Pharmaceuticals, LLC, EndoCeutics, Inc., and Radius Health, Inc. bring innovation and modernization to the competitive landscape.
These menopause treatment suppliers always fight to develop better treatment choices, address upcoming medical requirements, and enhance patient outcomes. The competition aids the market for advanced innovation, stimulates research and development, and ultimately benefits individuals looking for menopause treatments.
It can be inferred that as menopause treatment providers continue to tread through the menopause treatment market complexities, a foundation is laid for advancements and improvements resulting in treatment for better women's health.
Noteworthy Progressions
| Company | Details |
|---|---|
| Astellas Pharma Inc. | VEOZAH (fezolinetant) by Astellas Pharma Inc. received FDA approval, the first of its kind nonhormonal neurokinin 3 (NK3) receptor antagonist, in May 2023. VEOZAH is used to treat vasomotor symptoms (VMS) created due to menopause. |
| Amyris, Inc. | Amyris, Inc. bought MenoLabs, LLC in March 2022. MenoLabs, LLC treated women experiencing menopause and conducted research. Amyris, Inc. increased the range of menopausal treatment products it offers owing to the acquisition. |
| Pfizer Inc. | In May 2021, the United States Food and Drug Administration (FDA) authorized MYFEMBREE® to Myovant Sciences and Pfizer Inc. It was the first daily medicine for premenopausal women associated with the problem of excessive menstrual bleeding linked with uterine fibroids. |
| Bayer AG | Bayer AG announced in March 2020 that it acquired KaNDy Therapeutics, a prominent provider of women's healthcare goods, including menopause treatment products. The acquisition significantly strengthened its line of women's healthcare products. |
| Amgen | The FDA approved EVENITY (romosozumab-aqqg) in April 2019 by Amgen to treat postmenopausal osteoporosis. Women are prone to osteoporosis fractures more often than males, particularly after menopause. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The menopause wellness market to acquire a valuation of US$ 758.5 million in 2024.
The menopause treatment product market has the potential to garner a worth of US$ 1,308.00 million by 2034.
The menopause wellness market equates to a moderate CAGR of 5.6% through 2034.
From 2019 to 2023, the menopause treatment product market evolved at a CAGR of 7.8%.
The oral sector is set to possess a market share of 58.8% in 2024.
The hormone therapy segment to garner a market share of 62.4% in 2024.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Product, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Product, 2024 to 2034 5.3.1. Hormone Therapy 5.3.1.1. Combination 5.3.1.2. Tibolone 5.3.1.3. Progestin 5.3.1.4. Estrogen 5.3.2. Non-Hormonal Therapy 5.3.2.1. Gabapentinoids 5.3.2.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 5.3.2.3. Selective Serotonin Reuptake Inhibitors (SSRI) 5.3.2.4. Others 5.4. Y-o-Y Growth Trend Analysis By Product, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Route of Administration, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Route of Administration, 2024 to 2034 6.3.1. Topical 6.3.2. Injectable 6.3.3. Oral 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034 7.3.1. Institutional Sales 7.3.1.1. Hospitals 7.3.1.2. Specialty Clinics 7.3.2. Retail Sales 7.3.2.1. Retail Pharmacies 7.3.2.2. Drug Stores 7.3.2.3. Supermarkets/ Hypermarkets 7.3.3. Online 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Product 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Product 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Product 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Product 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Product 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Product 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Product 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Product 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Product 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Product 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Product 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Product 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Product 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Product 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Product 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Product 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Product 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Product 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Product 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Product 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Product 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Product 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Product 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Product 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Product 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Product 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Product 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Product 16.22.2.2. By Route of Administration 16.22.2.3. By Distribution Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Product 16.23.2.2. By Route of Administration 16.23.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Eli Lilly and Company 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Merck KGaA 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Novartis AG 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Bayers AG 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Pfizer, Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Novo Nordisk 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Ascend Therapeutics 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Mylan N.V. [Viatris] 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Cipla, Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Glenmark Pharmaceuticals Ltd. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 18.1.11. MenoGeniX 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.11.5.2. Product Strategy 18.1.11.5.3. Channel Strategy 18.1.12. Perrigo Pharma International D.A.C. 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.12.5.2. Product Strategy 18.1.12.5.3. Channel Strategy 18.1.13. Ausio Pharmaceuticals, LLC 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.13.5.2. Product Strategy 18.1.13.5.3. Channel Strategy 18.1.14. EndoCeutics, Inc. 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 18.1.14.5.2. Product Strategy 18.1.14.5.3. Channel Strategy 18.1.15. Radius Health, Inc. 18.1.15.1. Overview 18.1.15.2. Product Portfolio 18.1.15.3. Profitability by Market Segments 18.1.15.4. Sales Footprint 18.1.15.5. Strategy Overview 18.1.15.5.1. Marketing Strategy 18.1.15.5.2. Product Strategy 18.1.15.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Menopause Treatment Market
